Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

J. M. Winter, J. L. Cameron, K. A. Campbell, M. A. Arnold, D. C. Chang, J. Coleman, M. B. Hodgin, P. K. Sauter, R. H. Hruban, T. S. Riall, et al., “1423 Pancreaticoduodenectomies for Pancreatic Cancer: A Single-Institution Experience,” Journal of Gastrointestinal Surgery, Vol. 10, No. 9, 2006, pp. 1199-1210.

has been cited by the following article:

  • TITLE: A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma

    AUTHORS: Dominic E. Sanford, Matthew R. Porembka, Roheena Z. Panni, Jonathan B. Mitchem, Brian A. Belt, Stacey M. Plambeck-Suess, Goldie Lin, David G. DeNardo, Ryan C. Fields, William G. Hawkins, Steven M. Strasberg, Craig Lockhart, Andrea Wang-Gillam, Simon Peter Goedegebuure, David C. Linehan

    KEYWORDS: Pancreatic Cancer; Zoledronic Acid; Myeloid-Derived Suppressor Cells

    JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.3, May 27, 2013

    ABSTRACT: Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by abundant granulocytic myeloid-derived suppressor cells (G-MDSC = CD45+/Lin﹣/CD33+/CD11b+/CD15+), which infiltrate tumors and suppress anti-tumor immunity. We have previously demonstrated in a murine model of PDAC that zoledronic acid (ZA) depletes G-MDSC resulting in decreased tumor growth and improved survival. We report here the results of a phase 1 clinical trial (NCT00892242) using ZA as neo-adjuvant, perioperative therapy in patients with non-metastatic, resectable pancreatic adenocarcinoma. Methods: Eligible PDAC patients received ZA (4 mg) IV 2 weeks prior to surgery. Patients then received 2 additional doses of ZA 4 weeks apart. Blood and bone marrow were obtained from patients prior to treatment with ZA and 3 months after surgery for analysis of G-MDSC by flow cytometry. Results: Twenty-three patients received pre-operative ZA with at least 6 months of follow-up. Only 15 PDAC patients had nonmetastatic PDAC, which was amenable to resection. ZA was well tolerated, and all adverse events were grade 1 or 2. The most common adverse events were fatigue, abdominal pain/discomfort, anorexia, and arthralgia. Of resected PDAC patients treated with ZA, 1- and 2-year overall survival (OS) was 85.7% and 33.3%, respectively, with a median OS of 18 months. This group had a 1- and 2-year progression-free survival (PFS) of 26.9% and 8.9%, respectively, with a median PFS of 12 months. The prevalence of G-MDSC was unchanged in the blood and bone marrow of PDAC patients pre- and post-treatment with ZA. Conclusion: ZA is safe and well tolerated as neo-adjuvant, peri-operative therapy in PDAC patients. In this small study, we did not observe a difference in OS or PFS compared to historical controls. Also, there was no difference in the prevalence of G-MDSC in the blood and bone marrow of PDAC patients pre- and post-treatment with ZA.